Dropouts in Placebo Groups Due to Adverse Events Are Low in MG Clinical Trials, Study Shows
Placebo-treated myasthenia gravis (MG) patients experience as many adverse events as those receiving an active treatment during clinical trials, but this leads to few participant dropouts — and should not represent a problem for patient compliance to placebo during trials, a grouped analysis of studies shows. The study, “…